NeurologyJune 6, 2019
Mustering a Cell’s Internal Defenses Might Hold Potential for New Parkinson’s Disease Therapies
Rescue proteins could rid cell of toxic alpha-synuclein aggregates
Neurology
NeurologyMay 16, 2019
Autism May Be Diagnosed by Age Two
New study suggests that early screening may benefit some children
SAVE $80 ON AN UNLIMITED SUBSCRIPTION TODAY!
NeuroscienceMay 14, 2019
Thwarting a Protein Reverses Brain Decline in Aged Mice
Blocking an immune-related molecule lodged in blood vessels stops memory loss
MedicineMay 2, 2019
Experimental Autism Drugs Aim to Improve Social Communication Skills
Experts caution that addressing lingering questions will require more research.
BiotechMay 1, 2019
AI Tool Could Help Diagnose Alzheimer’s
A new algorithm accurately identified more than 90 percent of people who would advance to an Alzheimer’s diagnosis in about six years
NeurologyMay 1, 2019
The Sleep-Dementia Connection
Could a better nighttime rest help delay the symptoms of Alzheimer’s disease?
NeuroscienceApril 12, 2019
Behind the Buzz: How Ketamine Changes the Depressed Patient’s Brain
The anesthetic-cum-party drug restores the ability to make connections among brain cells
BiotechApril 10, 2019
A New Way to Detect Parkinson’s—by Smell
Discovery of odorous markers for neurodegenerative disease
BehaviorApril 5, 2019
Cyberchondriacs Just Know They Must Be Sick
Researchers are unraveling the psychological reasons why some people relentlessly self-diagnose themselves online for hours a day
Mental HealthApril 1, 2019
A Three-Hour Fix for Phobia, a Four-Day Therapy for OCD
Brief but intensive treatments are proving to be effective for many anxiety disorders
MedicineMarch 28, 2019
A Repurposed Drug Could Offer Hope after Many Alzheimer's Trial Failures
An experimental drug for hepatitis D triggers a cellular waste disposal system to rid mice brains of the tau protein, a major culprit in neurodegenerative disease
MedicineMarch 22, 2019
Biogen Halts Studies of Closely Watched Alzheimer’s Drug, a Blow to Hopes for New Treatment
Trial failure raises doubts about amyloid as a target for drug development